ZEOX (Zeo ScientifiX) Moat Score: 3/10 (As of Jul. 02, 2026)


ZEOX Zeo ScientifiX Inc ZEOX
52 GF Score
Price $1.90
GF Value $2.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Zeo ScientifiX Moat Score?

Zeo ScientifiX ZEOX +7.34% 52 Moat Score is 3 as of Jul. 02, 2026. GuruFocus rates ZEOX with a GF Score™ of 52/100 and a GF Value™ of $2.67 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,400 Biotechnology companies, Zeo ScientifiX ranks better than 75.5% on this metric.

Zeo ScientifiX has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Zeo ScientifiX has No Moat: Zeo ScientifiX Inc has a weak market position with minimal customer loyalty and network effects. The company lacks valuable intellectual property and durable cost advantages, resulting in weak and transient competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zeo ScientifiX might have No Moat - Very weak/transient advantages.

Zeo ScientifiX  (OTCPK:ZEOX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zeo ScientifiX Moat Score Related Terms

ZEOX vs JUNS, HOOK, LEXX: Moat Score Comparison

For the Biotechnology subindustry, Zeo ScientifiX's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zeo ScientifiX Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Moat Score distribution charts can be found below:

* The bar in red indicates where Zeo ScientifiX's Moat Score falls into.


ZEOX
52GF Score
Zeo ScientifiX Inc ZEOX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Zeo ScientifiX (ZEOX) has a Moat Score of 3 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Zeo ScientifiX ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Zeo ScientifiX's Moat Score too high?
Zeo ScientifiX's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Zeo ScientifiX's value of 3 is 50% above this industry median. Based on the distribution chart, Zeo ScientifiX ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zeo ScientifiX has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Moat Score compare to JUNS and HOOK?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #343 out of 1400 companies for Moat Score. This places Zeo ScientifiX in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Zeo ScientifiX's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.67, compared to a current price of $1.90 — trading 28.8% below its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Zeo ScientifiX's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Moat Score is 3 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zeo ScientifiX (ZEOX) Overvalued in 2026?

Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued. The current stock price of $1.90 is trading 28.8% below its estimated GF Value™ of $2.67. GuruFocus considers Zeo ScientifiX to be Modestly Undervalued.

Key valuation signals for ZEOX:

  • Moat Score: 3
  • GF Value™: $2.67 vs. price of $1.90 (28.8% below fair value)
  • GF Score™: 52/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1400)

No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zeo ScientifiX Business Description

Address 3321 College Avenue, Suite 246, Davie, FL, USA, 33314
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
52GF Score

Get the complete analysis for ZEOX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price
$2.67
GF Value